A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if BMS-232632 administered as
Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including
Lopinavir/ritonavir (LPV/RTV), as assessed by an increased brachial artery flow-mediated
vasodilatation (FMD), in HIV-infected patients. The safety of this treatment will also be
studied.